Post-marketing Registry to Assess Usage Information, Safety and Effectiveness of Deltyba® Tablets in Korean Patients With Pulmonary MDR-TB
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Delamanid (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors Korea Otsuka Pharmaceutical
- 12 Nov 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 12 Nov 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
- 21 Mar 2018 New trial record